SCHEMBL1383872

SCHEMBL1383872

Cc1cc(C(=O)NCCc2cccc(F)c2)c(C)n1-c1ccccc1C(F)(F)F

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 2/20 0.56
CNR1 P21554 1/20 0.56
CCR1 P32246 1/20 0.45
LMNA P02545 3/20 0.44
ALDH1A1 P00352 2/20 0.42
TP53 P04637 1/20 0.42
NOTUM Q6P988 2/20 0.41
NAMPT P43490 1/20 0.41
MYC P01106 1/20 0.41
POLB P06746 1/20 0.40
THRB P10828 1/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
KDM4E B2RXH2 1/20 0.39
HPGD P15428 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
HTR7 P34969 1/20 0.39
ABCB1 P08183 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1382218 0.91 CNR2 (0.68) CNR2CNR1CCR1LMNAALDH1A1
SCHEMBL1383544 0.90 CNR2 (0.58) CNR2CNR1CCR1LMNAALDH1A1
SCHEMBL1379284 0.90 CCR1 (0.56) CNR2CNR1CCR1LMNANOTUM
SCHEMBL1381839 0.89 CNR2 (0.55) CNR2CNR1CCR1LMNAALDH1A1
SCHEMBL27674124 0.89 CNR2 (0.57) CNR2CNR1CCR1LMNAALDH1A1
SCHEMBL1381101 0.88 CNR2 (0.53) CNR2CNR1CCR1TP53THRB
SCHEMBL1380205 0.87 CNR2 (0.59) CNR2CNR1CCR1LMNAALDH1A1
SCHEMBL1384403 0.85 CNR2 (0.57) CNR2CNR1CCR1LMNAALDH1A1
SCHEMBL1380081 0.85 CNR2 (0.57) CNR2CNR1CCR1LMNATP53
SCHEMBL1382070 0.85 CNR2 (0.59) CNR2CNR1CCR1ALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4703649-B2 2011-06-15 JP claimed
US-8026237-B2 For modulating activity of one or more steroid nuclear receptors and for treatment, prevention, or amelioration of symptoms of disease or disorder related to the activity of receptors; 5-benzo[b]thiophen-2-yl-1,4-dimethyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl)-amide EXELIXIS, INC. (US) 2011-09-27 US disclosed
US-8026237-B2 For modulating activity of one or more steroid nuclear receptors and for treatment, prevention, or amelioration of symptoms of disease or disorder related to the activity of receptors; 5-benzo[b]thiophen-2-yl-1,4-dimethyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl)-amide EXELIXIS, INC. (US) 2011-09-27 US disclosed
US-8026237-B2 For modulating activity of one or more steroid nuclear receptors and for treatment, prevention, or amelioration of symptoms of disease or disorder related to the activity of receptors; 5-benzo[b]thiophen-2-yl-1,4-dimethyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl)-amide EXELIXIS, INC. (US) 2011-09-27 US disclosed
US-20080234270-A1 Pyrrole Derivatives As Pharmaceutical Agents EXELIXIS, INC. (US) 2008-09-25 US disclosed
US-20080234270-A1 Pyrrole Derivatives As Pharmaceutical Agents EXELIXIS, INC. (US) 2008-09-25 US disclosed
US-20080234270-A1 Pyrrole Derivatives As Pharmaceutical Agents EXELIXIS, INC. (US) 2008-09-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080234270-A1 Pyrrole Derivatives As Pharmaceutical Agents PRLHR, PTGDR, TACR1 CNR2 13/4885CNR1 8/4885CCR1 1477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.